

# Conducting Investigator Initiated Trials in low Resource Settings – the Southern perspective

Ally Olotu MD PhD.

Ifakara Health Institute

Swiss TPH Summer Symposium 28<sup>th</sup> June 2018

Basel, Switzerland




## Definition of Investigator's initiated trials (ITT)

- Trials developed and sponsored by an independent investigator or academic sponsor.
- Industry support
  - Funding
  - Investigational Product/diagnostic
  - Monitoring?
- Funding source can be from other non-industry sources



## Non-industry initiated trials



#### THE UTILITY OF ITT IN AFRICA



#### ITTs expand product knowledge

# The NEW ENGLAND JOURNAL of MEDICINE

**ESTABLISHED IN 1812** 

JUNE 30, 2016

VOL. 374 NO. 26

#### Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children

Ally Olotu, Ph.D., Gregory Fegan, Ph.D., Juliana Wambua, M.Sc., George Nyangweso, B.Sc., Amanda Leach, M.R.C.P.C.H., Marc Lievens, M.Sc., David C. Kaslow, M.D., Patricia Njuguna, M.Med., Kevin Marsh, F.R.C.P., and Philip Bejon, Ph.D.

The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

## Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

D.E. Neafsey, M. Juraska, T. Bedford, D. Benkeser, C. Valim, A. Griggs, M. Lievens,
S. Abdulla, S. Adjei, T. Agbenyega, S.T. Agnandji, P. Aide, S. Anderson, D. Ansong,
J.J. Aponte, K.P. Asante, P. Bejon, A.J. Birkett, M. Bruls, K.M. Connolly,
U. D'Alessandro, C. Dobaño, S. Gesase, B. Greenwood, J. Grimsby, H. Tinto,
M.J. Hamel, I. Hoffman, P. Kamthunzi, S. Kariuki, P.G. Kremsner, A. Leach, B. Lell,
N.J. Lennon, J. Lusingu, K. Marsh, F. Martinson, J.T. Molel, E.L. Moss, P. Njuguna,
C.F. Ockenhouse, B. Ragama Ogutu, W. Otieno, L. Otieno, K. Otieno,
S. Owusu-Agyei, D.J. Park, K. Pellé, D. Robbins, C. Russ, E.M. Ryan, J. Sacarlal,
B. Sogoloff, H. Sorgho, M. Tanner, T. Theander, I. Valea, S.K. Volkman, Q. Yu,

D. Lapierre, B.W. Birren, P.B. Gilbert, and D.F. Wirth

OPEN 3 ACCESS Freely available online



#### Duration of Protection Against Clinical Malaria Provided by Three Regimens of Intermittent Preventive Treatment in Tanzanian Infants

Matthew Cairns<sup>1</sup>\*, Roly Gosling<sup>2</sup>, Ilona Carneiro<sup>2</sup>, Samwel Gesase<sup>3</sup>, Jacklin F. Mosha<sup>4</sup>, Ramadhan Hashim<sup>3</sup>, Harparkash Kaur<sup>2</sup>, Martha Lemnge<sup>3</sup>, Frank W. Mosha<sup>4</sup>, Brian Greenwood<sup>2</sup>, Daniel Chandramohan<sup>2</sup>

1 Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom, 2 Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom, 3 National Institute for Medical Research, Tanga Centre, Tanga, Tanzania, 4 Kilimanjaro Christian Medical College, Moshi, Tanzania





Volume 200, Issue 11 1 December 2009

#### Selection of Parasites with Diminished Drug Susceptibility by Amodiaquine-Containing Antimalarial Regimens in Uganda ••

Fatima Nawaz, Samuel L. Nsobya, Moses Kiggundu, Moses Joloba, Philip J. Rosenthal

The Journal of Infectious Diseases, Volume 200, Issue 11, 1 December 2009, Pages 1650–1657, https://doi.org/10.1086/647988

Published: 01 December 2009 Article history ▼

# Identify new indications/regimens of existing medical interventions.

The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

#### Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa

J.D. Keenan, R.L. Bailey, S.K. West, A.M. Arzika, J. Hart, J. Weaver, K. Kalua, Z. Mrango, K.J. Ray, C. Cook, E. Lebas, K.S. O'Brien, P.M. Emerson, T.C. Porco, and T.M. Lietman, for the MORDOR Study Group\*

Articles

Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea





Michael Marks, Oriol Mitjà, Christian Bottomley, Cynthia Kwakye, Wendy Houinei, Mathias Bauri, Paul Adwere, Abdul A Abdulai, Fredrick Dua, Laud Boateng, James Wangi, Sally-Ann Ohene, Regina Wangnapi\*, Shirley V Simpson, Helen Miag, Kennedy K Addo, Laud A Basing, Damien Danavall, Kai H Chi, Allan Pillay, Ronald Ballard, Anthony W Solomon, Cheng Y Chen, Sibauk V Bieb, Yaw Adu-Sarkodie, David C W Mabey, Kingsley Asiedu, on behalf of the study team\*



# The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JUNE 30, 2011

VOL. 364 NO. 26

#### Mortality after Fluid Bolus in African Children with Severe Infection

Kathryn Maitland, M.B., B.S., Ph.D., Sarah Kiguli, M.B., Ch.B., M.Med., Robert O. Opoka, M.B., Ch.B., M.Med., Charles Engoru, M.B., Ch.B., M.Med., Peter Olupot-Olupot, M.B., Ch.B., Samuel O. Akech, M.B., Ch.B., Richard Nyeko, M.B., Ch.B., M.Med., George Mtove, M.D., Hugh Reyburn, M.B., B.S., Trudie Lang, Ph.D., Bernadette Brent, M.B., B.S., Jennifer A. Evans, M.B., B.S., James K. Tibenderana, M.B., Ch.B., Ph.D., Jane Crawley, M.B., B.S., M.D., Elizabeth C. Russell, M.Sc., Michael Levin, F.Med.Sci., Ph.D., Abdel G. Babiker, Ph.D., and Diana M. Gibb, M.B., Ch.B., M.D., for the FEAST Trial Group\*





#### Increase local knowledge of diseases.



RESEARCH ARTICLE

6





Contents lists available at ScienceDirect

#### Papillomavirus Research


journal homepage: www.elsevier.com/locate/pvr



# A micro-epidemiological analysis of febrile malaria in Coastal Kenya showing hotspots within hotspots

Philip Bejon<sup>1,2\*</sup>, Thomas N Williams<sup>1,3</sup>, Christopher Nyundo<sup>1</sup>, Simon I Hay<sup>4</sup>, David Benz<sup>4</sup>, Peter W Gething<sup>4</sup>, Mark Otiende<sup>1</sup>, Judy Peshu<sup>1</sup>, Mahfudh Bashraheil<sup>1</sup>, Bryan Greenhouse<sup>5</sup>, Teun Bousema<sup>6,7</sup>, Evasius Bauni<sup>1</sup>, Kevin Marsh<sup>1,2</sup>, David L Smith<sup>8</sup>, Steffen Borrmann<sup>1,9,10</sup>

<sup>1</sup>KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; <sup>2</sup>Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom; <sup>3</sup>Imperial College London, London, United Kingdom; <sup>4</sup>Spatial Ecology and Epidemiology Group, Department of Zoology, University of Oxford, Oxford, United Kingdom; <sup>5</sup>Department of Medicine, University of California, San Francisco, San Francisco, United States; <sup>6</sup>Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; <sup>7</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom; <sup>8</sup>John Hopkins Malaria Research Institute, Baltimore, United States; <sup>9</sup>Institute for Tropical Medicine, University of Tübingen, Germany; <sup>10</sup>German Centre for Infection Research, Tübingen, Germany





Staci L. Sudenga<sup>a</sup>, B. Nelson Torres<sup>a</sup>, Matthys H. Botha<sup>b</sup>, Michele Zeier<sup>c</sup>, Martha E. Abrahamsen<sup>a</sup>, Richard H. Glashoff<sup>d</sup>, Susan Engelbrecht<sup>d</sup>, Maarten F. Schim Van der Loeff<sup>c</sup>, Louvina E. Van der Laan<sup>b</sup>, Siegfried Kipping<sup>b</sup>, Douglas Taylor<sup>f</sup>, Anna R. Giuliano<sup>a,\*</sup>

- <sup>a</sup> Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA
- b Department of Obstetrics and Gynaecology and Unit for Gynaecological Oncology, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa
- <sup>c</sup> Department of Medicine and Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa
- d Division of Medical Virology, Stellenbosch University and NHLS Tygerberg, Cape Town, South Africa
- <sup>c</sup> Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
- f FHI 360, Durham, NC, USA

# An evaluation of clinical indicators for severe paediatric illness

L.A. Paxton, S.C. Redd, R.W. Steketee, J.O. Otieno, & B. Nahlen

# Brain swelling and ischaemia in Kenyans with cerebral malaria

C R J C Newton, N Peshu, B Kendall, F J Kirkham, A Sowunmi, C Waruiru, I Mwangi, S A Murphy, K Marsh



# Compliment industry-sponsored clinical trial data to inform policy change considerations.

Wellcome Open Research

Wellcome Open Research 2018, 2:100 Last updated: 16 JAN 2018



STUDY PROTOCOL

**Children's Oxygen Administration Strategies Trial (COAST):** A randomised controlled trial of high flow versus oxygen versus control in African children with severe pneumonia [version 2;

referees: 2 approved]

IFAKARA HEALTH INSTITUTE

research | training | services

Kathryn Maitland <sup>101,2</sup>, Sarah Kiguli<sup>3</sup>, Robert O. Opoka<sup>3</sup>, Peter Olupot-Olupot<sup>4,5</sup>, Charles Engoru<sup>6</sup>, Patricia Njuguna<sup>2</sup>, Victor Bandika<sup>7</sup>, Ayub Mpoya<sup>2</sup>, Andrew Bush<sup>1,8</sup>, Thomas N. Williams 1,2, Richard Grieve, Zia Sadique, John Fraser, John Fraser, David Harrison<sup>11</sup>, Kathy Rowan<sup>11</sup>

Mbuagbaw et al. Trials 2011, 12:5 http://www.trialsjournal.com/content/12/1/5



#### STUDY PROTOCOL

**Open Access** 

The cameroon mobile phone sms (CAMPS) trial: a protocol for a randomized controlled trial of mobile phone text messaging versus usual care for improving adherence to highly active anti-retroviral therapy

Lawrence Mbuagbaw<sup>1\*</sup>, Lahana Thabane<sup>2,3</sup>, Pierre Ongolo-Zogo<sup>1</sup>, Richard T Lester<sup>4,5</sup>, Edward Mills<sup>6</sup>, Jimmy Volmink<sup>7</sup>, David Yondo<sup>1</sup>, Marie José Essi<sup>1</sup>, Renée-Cecile Bonono-Momnougui<sup>1</sup>, Robert Mba<sup>1</sup>, Jean Serge Ndongo<sup>1</sup>, Francois C Nkoa<sup>1</sup>, Henri Atangana Ondoa<sup>1</sup>

**Articles** 

Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial



James A Berkley, Moses Ngari, Johnstone Thitiri, Laura Mwalekwa, Molline Timbwa, Fauzat Hamid, Rehema Ali, Jimmy Shanqala, Neema Mturi, Kelsey D J Jones, Hassan Alphan, Beatrice Mutai, Victor Bandika, Twahir Hemed, Ken Awuondo, Susan Morpeth, Samuel Kariuki, Gregory Fegan





# Strengthen human & capacity infrastructure



#### Ideal IITs in Africa

- Be more applicable to local populations and build on local healthcare knowledge.
- Respond to local/regional needs and driven by a national agenda.
- Should influence policy and sustainably link research to action.
- Should involve local staff at all levels and stages of trial conduct,
  - Opportunity for 'learning by doing' and skill development



## Barriers to Investigator Initiated trials in Africa

- Inadequate capacity for clinical research (human resources and infrastructure)
  - Lack of appropriately trained clinical scientists and career structure to support them.
  - Lack of motivation/incentives & competing interests.
  - Lack of appropriate facilities and infrastructure.
  - Operational barriers.
- Lack of adequate and appropriate funding
  - Inadequate funding for clinical trials and other types of clinical research



## Barriers to Investigator Initiated trials in Africa

- Inadequate public engagement with clinical research.
  - Insufficient public promotion of clinical research by Government
  - Insufficient engagement by researcher with research participants and policymakers.
- Lack of research planning, regulation and coordination.
  - Lack of a coordinated national plan to balance excellence on the world stage with relevance to local problems;
  - An inefficient regulatory framework for clinical trials and registration of new medicines hindering the conduct of innovative clinical trials.



## Addressing the barriers to ITT in Africa

- Increase and maintain the supply of skilled clinical researchers.
  - Strengthening of biomedical research in universities and health care institutions.
  - Increase motivation and incentives.
- Increase funding in IIT and strengthening translational research.
  - Government, industry and non-industry funding.
  - Local and international collaborations.
- Close cooperation between researchers and health policymakers.
  - Define priority areas that need ITT to address
  - Improves uptake into policy.



#### Addressing the barriers to ITT in Africa.

- Increase awareness of health research and its impact.
  - Secondary-school and tertiary-school science education.
  - Improved health research profile among policy makers, the media and the public.
- Improve the research infrastructure.
- Inclusive trial operations.
  - Research conducted within local institutions
  - Use of local staff
  - Financial and material resources routed through local institution.



Fig. 1.3. Regional ranking of leading causes of disease burden, measured in disability-adjusted life-years (DALYs), 2011

Cause	African	Americas	South-East Asia	European	Eastern Mediterranean	Western Pacific	Global
Lower respiratory infections	1	9	1	14	1	10	1
HIV/AIDS	2	19	15	16			6
Diarrhoeal diseases	3		3		3		4
Malaria	4						13
Preterm birth complications	5	13	4		2	15	5
Birth asphyxia and birth trauma	6		7		5	17	9
Protein-energy malnutrition	7				18		
Meningitis	8				20		
Congenital anomalies	9	12	10	19	9	14	11
Road injury	10	5	8	8	7	4	8
Neonatal sepsis and infections	11		20		13		
Iron-deficiency anaemia	12		11		11		15
Stroke	13	6	6	2	8	1	3
Endocrine, blood, immune disorders	14	16			17		
Maternal conditions	15						
Ischaemic heart disease	16	1	2	1	4	2	2
Tuberculosis	17				14	20	16
Unipolar depressive disorders	18	2	12	3	6	5	10
Interpersonal violence	19	3					
Epilepsy	20						

Ranking legend 1–5 6–14 15–20 No ranking

#### **THANK YOU**

